Obsidian Therapeutics Enrolls First Participant In Its Phase 1/2 Agni-01 Trial Of Amsokigene Autoleucel To Treat Advanced Or Metastatic Melanoma

뉴스 본문을 불러오고 있어요.

Obsidian Therapeutics Enrolls First Participant In Its Phase 1/2 Agni-01 Trial Of Amsokigene Autoleucel To Treat Advanced Or Metastatic Melanoma | 웨이프 WAPE

Obsidian Therapeutics Enrolls First Participant In Its Phase 1/2 Agni-01 Trial Of Amsokigene Autoleucel To Treat Advanced Or Metastatic Melanoma

기사 요약

관련 종목

댓글 —